Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321

Journal of Clinical Oncology

Volumn 24, Issue 6, 2006, Pages 929-936

  Barlogie, Bart ^a   Kyle, Robert A ^a   Anderson, Kenneth C ^a   Greipp, Philip R ^a   Lazarus, Hillard M ^a   Hurd, David D ^a   McCoy, Jason ^a   Dakhil, Shaker R ^a   Lanier, Keith S ^a   Chapman, Robert A ^a   Cromer, Jeana N ^a   Salmon, Sydney E ^a   Durie, Brian ^a   Crowley, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERFERON; MELPHALAN; MESNA; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; M 2 PROTOCOL; M-2 PROTOCOL;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTONOMIC NEUROPATHY; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIVERTICULITIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; INFECTION; INTERMETHOD COMPARISON; IRRITABILITY; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG EDEMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROPATHY; OPTIMAL DRUG DOSE; PAIN; PERICARDITIS; PERITONITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SENSORIMOTOR NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; WHOLE BODY RADIATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT FAILURE; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERONS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 33644920953     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.5807     Document Type: Article

References (36)

1. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
2. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883, 2003
3. Fermand JP, Ravaud P, Katsahian S, et al: High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): Results of a randomized trial in 190 patients aged 55 to 65 years of age. Blood 94:396a, 1999 (suppl 1, abstr 1754)
4. Blade J, Rosinol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759, 2005
5. Oken MM, Harrington DP, Abramson N, et al: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 79:1561-1567, 1997
6. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
7. Blade J, Samson D, Reece D, et al: Criteria for evaluating response in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 102: 1115-1123, 1998
8. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1973
9. Kaplan EL, Meier R: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
11. Anderson GL, LeBlanc M, Liu PY, et al: On use of covanates in randomization and analysis of clinical trials, in Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, NY, Taylor and Francis, 2005
12. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
13. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myeloma 9502 randomized clinical trial. Blood 99:731-735, 2002
14. Desikan KR, Tricot G, Dhodapkar M, et al: Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 25:483-487, 2000
15. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
16. Fassas A, Shaughnessy J, Barlogie B: Cure of myeloma: Hype or reality? Bone Marrow Transplant 35:215-224, 2005
17. Salmon SE, Tesh D, Crowley J, et al: Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 9:705-707, 1991
18. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430-1434, 1990
19. The Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020-1034, 2001
20. Fritz E, Ludwig H: Interferon-alfa treatment in multiple myeloma: Meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 11:1427-1436, 2000
21. Greipp PR, San Miguel J, Durie BG, et al: An International Staging System (ISS) for multiple myeloma (MM). J Clin Oncol 23:3412-3429, 2005
22. Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993
23. Shaughnessy J, Tian E, Sawyer J, et al: Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 120:44-52, 2003
24. Facon T, Avet-Loiseau H, Guillerm G, et al: Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566-1571, 2001
25. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
26. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
27. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39, 2005
28. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
29. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Blood 104: 155a, 2004 (abstr 535)
30. Bensinger W: Stem cell transplantation for multiple myeloma. Int J Hematol 77:232-238, 2003
31. Gahrton G, Svensson H, Cavo M, et al: Progress in allogeneic bone marrow and peripheral stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113:209-216, 2001
32. Badros A Barlogie B, Siegel E, et al: Improved outcome of non-myeloablative allogeneic transplantation in multiple myeloma. J Clin Oncol 20:1295-1303, 2002
33. Maloney DG, Molina AJ, Sahebi F, et al: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447-3454, 2003
34. Kroeger N, Sayer HG, Schwerdtfeger R, et al: Unrelated stem cell transplantation after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100:3919-3924, 2002
35. Lee CK, Badros A, Barlogie B, et al: Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 31:73-80, 2003
36. Shaughnessy J Jr, Zhan F, Barlogie B, et al: Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol 18:537-552, 2005